Delivery Order SPE2DB20D9354-SPE2DB25FX7U9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $18,149.94 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation. The award represents a discrete purchase order issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,132.25 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries an ultimate completion date of September 30, 2025, and was awarded on September 9, 2025, with no set-aside designation applied. DMS Pharmaceutical Group will perform the work at its Park Ridge facility, delivering...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, valued at $18,238.39, was awarded on August 7, 2025, with an ultimate completion date of August 28, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its...
- The Defense Logistics Agency awarded a delivery order valued at $36,122.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contractual relationship with the...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $15,860.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $35,824.80 to DMS Pharmaceutical Group Inc. on June 16, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, with an ultimate completion date of July 9, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contract vehicle with DLA. The award carries no set-aside designation, allowing the woman-owned small business to compete on an unrestricted...
- The Defense Logistics Agency awarded a $18,273.77 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 24, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge facility with an ultimate completion date of August 14, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group...
- The Defense Logistics Agency (DLA) awarded a $18,132.25 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract was awarded on September 15, 2025, with an ultimate completion date of October 6, 2025, under a firm fixed-price arrangement with no set-aside designation. Performance will occur at the vendor's facility in Park Ridge, Illinois. This delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $15,753.25 by the Defense Logistics Agency on August 15, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries a firm fixed-price structure with an ultimate completion date of September 8, 2025, and no set-aside designation was applied to this award. This delivery order will be performed at the vendor's facility in...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $18,019.40 by the Defense Logistics Agency (DLA) for the supply of Prolastin C 1,000 mg/20 ml vials. The contract employs firm fixed-price pricing with an ultimate completion date of September 8, 2025. This delivery order was issued without a set-aside designation, reflecting the company's competitive positioning within federal...
- SPE2DB20D9354Indefinite Delivery Contract
- SPE2DB20D9354-SPE2DB25FX7U9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $17,604.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on June 12, 2025, with an ultimate completion date of July 7, 2025, represents a discrete procurement action under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA. The contract carries no set-aside designation, allowing the vendor to compete on an unrestricted basis despite its small business status. The place of performance is located at the vendor's facility in Park Ridge, Illinois. DMS Pharmaceutical Group has established itself as a significant federal pharmaceutical supplier through its $500 million IDC with the Defense Logistics Agency under the SPE2DB program, which remains valid through November 2026. This delivery order for Prolastin C, an augmentation therapy product used in treating alpha-1 antitrypsin deficiency, exemplifies the company's role in supplying specialized pharmaceutical products to Department of Defense healthcare facilities nationwide. The vendor's extensive federal contracting portfolio demonstrates consistent success in securing delivery orders for branded and generic prescription drugs, biologics, and medical consumables that support military health system requirements across multiple therapeutic categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.6k | 6/12/25 |